Angle Losses Rise Due to Increased Investment Expenses | July 25, 2018

StockMarketWire.com – The Angle Liquid Biopsy Company has recorded a larger annual loss, due to the planned investment in its offering.

Pre-tax losses for the year to April amounted to 7.6 million pounds, compared with losses of 6.3 million a year earlier

an FDA clinical study of 400 was underway with four US cancer centers targeted. "With two successful studies on ovarian cancer, launching our clinical studies on the FDA and three global healthcare companies secure as partners, Angle has gained recognition and potential in the past. on a global scale, "said Garth Selvey

. ] "The acquisition of downstream analysis technology completes the Parsortix system and will allow us, ultimately, to offer our customers a complete" sample to respond "solution."

"We continue to invest heavily to obtain FDA clearance for the Parsortix system as the first FDA has authorized a clinical device to harvest intact tumor cells circulating for analysis from the patient's blood.

"The start of clinical trials at four prestigious US cancer centers is a big step forward.

At 14:50: [LON:AGL] The course of the Angle PLC's action was from -1.5p to 52.5p

History provided by StockMarketWire.com